Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report)'s stock price traded down 9% during mid-day trading on Tuesday after an insider sold shares in the company. The company traded as low as $12.25 and last traded at $12.28. 200,248 shares were traded during trading, a decline of 79% from the average session volume of 939,712 shares. The stock had previously closed at $13.49.
Specifically, insider
Barry Ticho sold 10,000 shares of the company's stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $4.80, for a total value of $48,000.00. Following the completion of the sale, the insider now directly owns 6,981 shares of the company's stock, valued at approximately $33,508.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through
the SEC website. In related news, CEO Edward M. Md Kaye sold 11,150 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $68,015.00. Following the sale, the chief executive officer now directly owns 69,350 shares in the company, valued at $423,035. The transaction was disclosed in a document filed with the SEC, which can be accessed through
this link. Also, insider
Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $4.80, for a total value of $48,000.00. Following the completion of the sale, the insider now owns 6,981 shares in the company, valued at $33,508.80. The disclosure for this sale can be found
here. Insiders have sold a total of 32,741 shares of company stock worth $223,115 in the last quarter. 12.30% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
STOK has been the subject of a number of analyst reports. Needham & Company LLC boosted their price target on Stoke Therapeutics from $14.00 to $22.00 and gave the stock a "buy" rating in a report on Tuesday, March 26th. JPMorgan Chase & Co. upped their target price on Stoke Therapeutics from $6.00 to $13.00 and gave the company a "neutral" rating in a research note on Tuesday, March 26th. TD Cowen upgraded Stoke Therapeutics from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 26th. HC Wainwright reiterated a "buy" rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, March 26th. Finally, Wedbush upped their target price on Stoke Therapeutics from $13.00 to $17.00 and gave the company an "outperform" rating in a research note on Tuesday, March 26th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $19.63.
Get Our Latest Report on Stoke Therapeutics
Stoke Therapeutics Price Performance
The stock has a market cap of $605.60 million, a PE ratio of -5.08 and a beta of 0.76. The business has a fifty day moving average of $6.58 and a 200 day moving average of $5.19.
Institutional Trading of Stoke Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp raised its position in shares of Stoke Therapeutics by 1.4% during the 1st quarter. Bank of New York Mellon Corp now owns 62,698 shares of the company's stock worth $1,320,000 after purchasing an additional 837 shares during the period. American International Group Inc. boosted its stake in shares of Stoke Therapeutics by 10.9% during the 2nd quarter. American International Group Inc. now owns 10,506 shares of the company's stock worth $139,000 after acquiring an additional 1,029 shares in the last quarter. Great West Life Assurance Co. Can boosted its stake in shares of Stoke Therapeutics by 46.7% during the 1st quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company's stock worth $28,000 after acquiring an additional 1,078 shares in the last quarter. Ensign Peak Advisors Inc bought a new stake in shares of Stoke Therapeutics during the 1st quarter worth $25,000. Finally, Point72 Hong Kong Ltd purchased a new stake in shares of Stoke Therapeutics in the first quarter valued at $27,000.
About Stoke Therapeutics
(
Get Free Report)
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
Read More
Before you consider Stoke Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.
While Stoke Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
